Clinuvel Pharmaceuticals (OTCMKTS:CLVLY) Stock Price Down 3.5% – Here’s Why

Clinuvel Pharmaceuticals Limited (OTCMKTS:CLVLY – Get Free Report)’s stock price was down 3.5% during mid-day trading on Tuesday . The company traded as low as $7.01 and last traded at $7.10. Approximately 3,500 shares traded hands during trading, an increase of 29% from the average session volume of 2,714 shares. The stock had previously closed at $7.36.

Clinuvel Pharmaceuticals Price Performance

The firm’s 50-day simple moving average is $6.70 and its 200 day simple moving average is $7.40.

About Clinuvel Pharmaceuticals

(Get Free Report)

Clinuvel Pharmaceuticals Limited is an Australian biopharmaceutical company headquartered in Melbourne, specializing in the development and commercialisation of photoprotective and phototherapeutic solutions. The company’s research centers on harnessing the skin’s natural photoprotective pathways by modulating the melanocortin system, with a view to addressing a range of skin disorders and conditions that are exacerbated by ultraviolet light exposure.

The company’s flagship product, Scenesse (afamelanotide), is the first systemic photoprotective drug approved by both the European Medicines Agency and the U.S.

Featured Stories

• Five stocks we like better than Clinuvel Pharmaceuticals
• Oracle’s Sell-Off Looks More Like a Mispricing Than a Warning
• Apple’s Intel Deal Arrives at the Right Time for Its Stock
• Liquid Gold: The AI Cooling Retrofit Trade
• 3 Dividend Stocks Under $30 to Anchor Your Portfolio

Receive News & Ratings for Clinuvel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clinuvel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.